Introduction
Lipoprotein lipase is the key enzyme of the plasma fat transport system. The enzyme, situated on the luminal surface of endothelial cells, hydrolyzes triglycerides in chylomicrons and VLDL, and causes transfer of the liberated fatty acids to the tissues ( 1) . The central role that lipoprotein lipase plays in lipoprotein metabolism is dramatically illustrated in patients with genetic defects ofthe enzyme and manifestations ofchylomicronemia and type I hyperlipoproteinemia (2) .
Another role for lipoprotein lipase in lipoprotein physiology was suggested in 1975 by Felts who proposed that the presence of the enzyme on the outer coat of lipoprotein remnant particles may direct the remnants to catabolism in the liver (3) . In a recent publication, Beisiegel et al. demonstrated 20-40- fold enhancement of the binding of human chylomicrons, rabbit f3-VLDL, and apo E-containing liposomes to cells when lipoprotein lipase was added to the incubation mixture (4).
These authors also reported increased binding of apo E liposomes to the a2 macroglobulin/LDL receptor-related protein (LRP) 1 in the presence of lipoprotein lipase.
In the present study we investigated another possibility, namely, that lipoprotein lipase enhances, predominantly, binding of lipoproteins to an abundant cell surface molecule rather than to lipoprotein receptors. The study unequivocally demonstrated that the major effect oflipoprotein lipase is on the binding of human plasma lipoproteins to heparan sulfate on cell surfaces and in the extracellular matrix. This interaction brings lipoproteins into close proximity with cell surfaces and may promote metabolic processes that occur at the cell surface.
Methods
Preparation of lipoproteins and iodinated lipoproteins. VLDL (d < 1.006 g/ml), IDL (d 1.006-1.019 g/ml), LDL (d 1.019-1.063 g/ ml), and HDL3 (d 1.1 125-1.21 g/ml) were separated sequentially from plasma obtained from normal human subjects after 12-14-h fast.
The apo E phenotype ofthe subjects was E 3/3 or E 4/3. Lipoproteins were separated by centrifugation in 6OTi or 5OTi rotors at 40C in an ultracentrifuge (model L5-50; Beckman Instruments Inc., Fullerton, CA) using standard techniques (5) . The lipoproteins were washed once at a heavy density solution. VLDL density subfractions were prepared on a NaCI gradient in an SW-41 rotor (Beckman Instruments) (6) . All lipoproteins were dialyzed against 0.15% NaCl, 20 mM Tris (pH = 7.4), 0.001% EDTA solution, were sterilized by passage through a 0.45-Am filter (Millipore Corp., Bedford, MA) and used within 10-14 d ofpreparation. Chylomicrons were collected from the plasma of normal human subjects 4 h after a meal administered at a morning hour after a 12-h fast. The meal contained -1,000 kcal with 60% of kcal from fat, 25% from carbohydrates, and 15% protein (7) . Chylomicrons were separated by a 30-min centrifugation in an SW41 rotor at 35 ,000 rpm and 40C and were washed in 0.9% NaCl solution by two additional spins, 20 min each. The amount of chylomicron-protein was 0.5-1.0 mg per 100 ml plasma. Lipoproteins were radioiodinated with Na'25I by the iodine monochloride method (8) as modified for labeling of lipoproteins (9) . The final specific activity of '25I-labeled lipoproteins varied between 100 and 600 cpm/ng protein. Ofthe radioactivity, 1 (10) . Total, free, and esterified cholesterol, total phospholipids and triglycerides were determined by standard procedures (5) . SDS-PAGE ofapolipoproteins was performed as described by Weber and Osborn ( 11) . The chemical composition and apolipoprotein profile of lipoproteins was similar to that described previously (5, 7, 12) .
Cell cultures and extracellular matrix (ECM). Normal human skin fibroblasts, skin fibroblasts from an LDL receptor-negative homozygous familial hypercholesterolemic patient, and hepG-2 cultures were maintained as described (5, 12 ( 13, 14) .
Dishes coated with a naturally produced ECM were prepared as previously described ( 15 ) . Cultures of bovine corneal endothelial cells were established from steer eyes ( 16), the cells (second to fifth passage) were plated in 16-mm or 35-mm plastic dishes and cultured in DMEM, ( 1 g glucose/liter) supplemented with 10% bovine calfserum, 5% FCS, and dextran T-40 (15, 17) . 6-8 d after the cells reached confluence, the cell layer was treated with PBS containing 0.5% Triton X-100 and 20 mM NH40H followed by four washes with PBS. The subendothelial ECM remained intact, attached to the entire area of the dish and was free of nuclear or cellular elements ( 15 ) . ECM-coated plates containing PBS were kept at 4VC for up to 3 mo. Metabolically sulfate (Na235SO4) labeled ECM was prepared as previously described ( 17) .
Materials. Lipoprotein lipase was purified from bovine milk by established procedures ( 18) . Recombinant basic fibroblast growth factor (bFGF) was kindly provided by Takeda Chemical Industries (Osaka, Japan) and iodinated ( 1.2 X I05 cpm/ng) by lodogen (Pierce Chemical Co., Rockford, IL) (17) and ECM were chilled on ice (60 min) and the LPDS-medium was removed and replaced after one wash with PBS by a new ice-cold minimal essential medium containing 5 mg BSA/ml and 20 mM Hepes (pH = 7.4). "2'I-lipoproteins (usually 5 ,ug/ml) and lipoprotein lipase were added to the medium immediately before initiation ofthe binding experiment. Binding was allowed to take place during 60 min incubation on ice. Thereafter, the medium was removed, the cells were washed three times in PBS-0.2% BSA and once in PBS. Bound lipoproteins were released at 0C by adding 0.9% NaCl, 10 mM Hepes (pH = 7) containing 5 mg/ml of sodium heparin for 1 h, according to Goldstein et al. (21 ) . The cells and ECM were dissolved in 0.5N NaOH and examined for radioactivity and protein content. In some experiments, labeled lipids in the cells were extracted with chloroform:methanol ( 1:1 vol/vol) ( 5 ). Culture dishes without cells and cultures incubated in the presence of 40-fold excess of unlabeled lipoproteins were processed in parallel and the values found were subtracted from the experimental values. Binding, cell association, and degradation of 125I-LDL in the absence and presence oflipoprotein lipase were determined as previously described (5, 12) . The incubation mixture was similar to that described above except that LPDS medium was used. At the end of 4-h incubation at 370C, the medium was removed and examined for noniodide 1251-protein degradation products (21) . The cells were chilled on ice and washed extensively with ice-cold PBS-0.2% BSA.
Bound 1251I-LDL in the washed cells was determined by release ofradioactivity with sodium-heparin as above, and cell-associated radioactivity was defined as counts remaining in the cells. Binding of 1251I-labeled lipoprotein lipase to cells at 0C was determined by the procedure described above for lipoproteins. To determine low affinity, presumably heparan sulfate binding of 125I-bFGF, confluent cell cultures were incubated (2 h, 4°C) in DMEM containing I mg/ml BSA, 20 mM Hepes, and 2.5 ng/ml 1251-bFGF ( 1.2 x I05 cpm/ng). The cells were washed twice with binding medium and incubated (5 min, 4°C) with a solution containing 1.6 M NaCI and 20 mM Hepes, pH 7.4 and the incubation medium was assessed for radioactivity ( 14) . Results
Lipoprotein lipase at a protein concentration of 0.5-1 tg/ml markedly promoted (up to -100-fold) binding of all human plasma lipoproteins tested (chylomicrons, VLDL-I, VLDL-III, intermediate density lipoprotein, LDL, and HDL3) (5 jg/ml) to normal human skin fibroblasts, LDL receptor-negative fibroblasts and hepG-2 cultures, except for binding of HDL to hepG-2 cells (Table I) . Lipoprotein lipase also promoted the binding ofall these lipoproteins to ECM (Table I To ascertain that the heparinase treatment has not inter- In an additional experiment an attempt was made to determine whether a 39-kD fusion protein that specifically inhibits the interactions of lipoproteins with the LRP ( 19) also inhibits the lipoprotein lipase enhanced binding oflipoproteins to cells. To this end, the effects of the 39-kD fusion protein on the lipoprotein lipase-enhanced binding of chylomicrons to hepa- rinase-treated normal and LDL receptor-negative skin fibroblasts was determined (Fig. 4) . No effect was observed. In other experiments no effects of the 39-kD fusion protein were found in fibroblasts not treated with heparinase (data not shown). The 39-kD fusion protein in contrast caused a 60% decrease of cholesterol esterification in the LDL receptor-negative fibroblasts after incubation with apo E-3 enriched rabbit f3-VLDL using the same conditions as described by Herz et al. (19) . The lipoprotein lipase-enhanced binding of lipoproteins to heparan sulfate could be related or unrelated to the catalytic activity of the enzyme. To clarify this question, experiments were performed on normal and LDL receptor-negative fibroblasts using catalytically inactive enzyme (Fig. 5) . Lipoprotein lipase was inactivated by an overnight incubation at 4-60C with 1 M guanidine as described in Methods. The inactive enzyme had no activity against rat plasma VLDL labeled bio- in the absence oflipoprotein lipase. An experiment on the binding of lipoprotein lipase itself to the cells (conducted with 125I-labeled enzyme treated exactly as the unlabeled enzyme) indicated that the partial inhibition ofbinding ofVLDL to the cells by the inactive enzyme is due to reduced ability of the guanidine-treated lipoprotein lipase to bind to heparan sulfate (Fig.  5) . It thus appears that the lipoprotein lipase-enhanced binding of lipoproteins to heparan sulfate is independent of the catalytic activity of the enzyme, at least in part.
Discussion
The structure oflipoprotein lipase, a triglyceride hydrolase that plays a key role in lipoprotein metabolism, has been elucidated in recent years (24) . The enzyme molecule contains several functional regions, including a lipid-binding region and a heparin/heparan sulfate-binding region (25) . The heparin-binding region appears to be responsible for binding of the enzyme to heparan sulfate on cell surfaces, while the lipid-binding region appears to be responsible for interaction of the enzyme with lipoprotein particles. The results of the present study are compatible with these notions. We suggest that lipoprotein lipase forms a "bridge" between lipoproteins and heparan sulfate on cell surfaces and extracellular matrix. This action is independent of the catalytic activity of the enzyme. Our experiments show that lipoprotein lipase bound to heparan sulfate retains its capacity to bind lipoproteins. It is also possible that lipoprotein lipase binds first to lipoprotein surfaces and then the lipoprotein-enzyme complex binds to the heparan sulfate. Either mechanism may be important in physiological reaction. For example, the first is responsible for triglyceride transport in tissues that express the lipoprotein lipase gene, and the second for clearance of lipoprotein-enzyme complexes such as chylomicron and VLDL remnants.
Several investigations indicated that lipoprotein lipase enhances the interaction of lipoproteins with cells. Studies from the Steins' laboratory have demonstrated that lipoprotein lipase promotes transfer of cholesteryl esters, their ether analogues, and ether analogues of phosphatidylcholine from various rat plasma lipoproteins and from liposomes to cells in culture (26) (27) (28) . The reaction presumably is mediated by enhancing the binding of the lipoproteins to cell surfaces. Lipoprotein lipase also readily binds to the subendothelial matrix (29) , retains its enzymatic activity (29) , and may be responsible for retention of LDL in the extracellular matrix (30) . Bei (17) , most likely because the latter enzyme exhibits a very strict interchain site specificity, yielding degradation fragments of higher molecular weight.
We show here that lipoprotein lipase enhances indiscriminately the binding ofall human lipoproteins studied to heparan sulfate on cell surfaces and ECM, although it appears to be especially active for triglyceride-rich lipoproteins. This is not surprising, as lipoprotein lipase induces lipid hydrolysis in all plasma lipoproteins, including LDL and HDL, during in vitro incubations (32, 33 ). Yet, in whole plasma, the effect may be almost totally restricted to triglyceride-rich lipoproteins that possess much higher affinity to lipoprotein lipase as compared to the cholesterol ester-rich lipoproteins, LDL and HDL (34) .
A crucial question that emerges from the present study is whether lipoprotein lipase-enhanced binding oflipoproteins to heparan sulfate is ofphysiological importance. To be ofphysiological metabolic relevance, lipoprotein lipase should not merely enhance the binding oflipoproteins to cell surfaces, but also promote uptake and degradation of the particles. Such effects were recently demonstrated by us in lipolyzed VLDL when the lipolysis process exposes unreactive apo E molecules on the VLDL and promotes uptake and degradation of the particles through the LDL receptor pathway (5) . In the present investigation we were not able to demonstrate a direct effect of lipoprotein lipase on the uptake and degradation of LDL through the LDL receptor in heparinase-treated normal human skin fibroblasts or through the LRP in LDL receptor-negative fibroblasts. While an effect on triglyceride-rich lipoproteins might have been observed, it is impossible to discern in experiments carried out at 370C between consequences oflipolysis of VLDL or chylomicrons (5, 7) and those due to the lipoprotein lipase molecule itself. Yet, lipoprotein lipase-enhanced binding of LDL to heparan sulfate caused a 50% increase ofthe proteolytic degradation ofthe lipoprotein, in normal skin fibroblasts, presumably by facilitated transfer of the LDL from the heparan sulfate to the LDL receptor. Effects of lipoprotein lipase on uptake and degradation of LDL were recently published. Aviram et al. reported enhanced metabolism of lipolyzed LDL in macrophages, smooth muscle cells, and normal skin fibroblasts, but not in LDL receptor-negative fibroblasts (35, 36) . In that study, the lipolyzed LDL was isolated by gel filtration and most probably retained enzyme molecules on its surface. Williams et al. (37) observed a lipoprotein lipase enhanced uptake and degradation of LDL (but not monoclonal antibody C-7) in hepG-2 cells. A similar lipoprotein lipase-enhanced degradation of LP(a) was also reported in an abstract from the same group of investigators (38) . The abstract states that the enhanced LP( a) degradation occurs predominantly through the LDL receptor pathway although some enhancement is also reported in LDL receptor-negative cells. In all these studies, a lipoprotein lipase-enhanced binding of the lipoprotein to heparan sulfate followed by facilitated transfer of the particles to receptors could have occurred but was not investigated. With chylomicrons and VLDL we found a 2-20-fold increase in binding to cell surface heparan sulfate that was abolished after heparinase treatment when using lipoprotein lipase concentrations as low as 10-50 ng/ml. These concentrations are certainly close to those found in preheparin human plasma (8-25 ng/ml) (39) and are below those measured in postheparin plasma, (-200 ng/ml) (40) . It is thus possible that under physiological conditions even small amounts oflipoprotein lipase bound to circulating lipoproteins may promote their interaction with heparan sulfate on cell surfaces and ECM.
Several studies have indicated that interaction of biologically active molecules with heparan sulfate and heparinlike molecules is obligatory for proper expression of their activity. For example, heparin/heparan sulfate is required for bFGF high affinity binding ( 14, 15) and for bFGF-induced cell proliferation and myoblast differentiation (23, 41) . Likewise, binding of vascular endothelial growth factor to its cell surface receptors has an absolute requirement for heparin and/or cell surface heparan sulfate (42). Not surprisingly, heparin and heparan sulfate proteoglycans are important regulators of cell growth and differentiation (43). Lipoprotein lipase mediated interactions oflipoproteins with heparan sulfate may also serve an important physiological function. As discussed above, such interaction could bring the lipoprotein into close proximity to cell surfaces and facilitate transfer of the particles to cellular receptors. It could also promote flux of lipid molecules between lipoproteins and cells and be responsible for influx of cholesteryl esters from the lipoproteins and effilux of unesterified cholesterol from the cells. A similar process could even be responsible for sequestration of chylomicron remnants in the liver (44), a phenomenon that recently was ascribed by Mahley and Hussain to interaction of the remnant particles with heparan sulfate on liver cells (45) . It is more difficult to assume a physiological role for lipoprotein lipase-mediated binding of lipoproteins to ECM. Yet, a possible biological impact of a similar process on accretion of lipoproteins in extracellular spaces, for example during atherogenesis, cannot be ruled out. Indeed, Saxena et al. (30) demonstrated increased retention of LDL on extracellular matrix when lipoprotein lipase is added to matrix plated below a cultured endothelial cell layer. Again, the possible role of binding ofthe lipase to heparan sulfate was not investigated but probably provides the mechanism responsible for the observed phenomenon. In this context, it is interesting to note that macrophages and smooth muscle cells in atheromas express the lipoprotein lipase gene (46) and that involvement of arterial lipoprotein lipase in atherogenesis was postulated by Dr. Zilversmit (47) . Evidently, the findings described in the present report warrant more extensive investigation of the role that lipoprotein lipase-mediated binding of lipoproteins to heparan sulfate plays in metabolic events that occur during lipoprotein-cell and lipoprotein-matrix interactions.
